Compositions comprising bacterial strains
The invention provides compositions comprising bacterial strains for treating and preventing cancer.
1. A pharmaceutical composition that comprises:
a therapeutically effective amount of a bacteria strain of the species Enterococcus gallinarum deposited under accession number NCIMB 42488; and
a pharmaceutically acceptable excipient, diluent, or carrier;
wherein said therapeutically effective amount of said bacteria strain is an amount sufficient for treating cancer in a subject, and
wherein said bacteria strain is lyophilized.
2. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable excipient, diluent, or carrier further comprises a lyoprotectant.
3. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises at least one additional bacteria strain.
4. The pharmaceutical composition of claim 1 , wherein at least 50% of said bacteria strain, as measured by an amount of colony forming units (CFU), remains viable after about 1 year of storage when said pharmaceutical composition is stored in a closed container at 25° C. at 95% relative humidity.
5. The pharmaceutical composition of claim 1 , wherein said therapeutically effective amount of said bacteria strain comprises from about 1×10 6 to about 1×10 11 CFU/g of said bacteria strain with respect to a total weight of said pharmaceutical composition.
6. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises a lipopolysaccharide.
7. The pharmaceutical composition of claim 1 , wherein said therapeutically effective amount is an amount effective to increase production of at least one cytokine selected from the group consisting of IL-6, TNF-α, and IL-1β.
8. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is formulated for oral delivery.
9. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises a prebiotic compound selected from the group consisting of: a fructo-oligosaccharide, a short-chain fructo-oligosaccharide, inulin, an isomalt-oligosaccharide, a transgalacto-oligosaccharide, a pectin, a xylo-oligosaccharide, a chitosan-oligosaccharide, a beta-glucan, an arable gum modified starch, a polydextrose, a D-tagatose, an acacia fiber, carob, an oat, and a citrus fiber.
10. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises an adjuvant.